Anti-il1r2 antibody, antigen-binding fragment thereof and use thereof

The screening of antibodies against IL1R2 through phage display technology solves the problem of large side effects and limited efficacy of existing CTLA-4 targeted inhibitors, and achieves effective inhibition and survival rate improvement of mouse tumors, providing new for tumor immunotherapy target.

WO2025025208A1PCT designated stage expired Publication Date: 2025-02-06SUZHOU INST OF SYST MEDICINE
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2023/110991
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-08-03
Publication Date
2025-02-06

AI Technical Summary

Technical Problem

In the existing tumor immunotherapy, although CTLA-4 targeted inhibitors have good clinical efficacy, they have large side effects and a low overall remission rate. New targets need to be found to make up for these shortcomings.

Method used

The human antibody library was constructed through phage display technology, specific antibodies against IL1R2 were screened out, and antibodies against IL1R2 or antigen-binding fragments were developed to enhance the body's anti-tumor immunity effect.

Benefits of technology

The screened antibodies can effectively inhibit the growth of tumors in mice, improve the overall survival rate of mice, and provide new targets and research directions for tumor immunotherapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2023110991_06022025_PF_FP_ABST
    Figure CN2023110991_06022025_PF_FP_ABST
Patent Text Reader

Abstract

An anti-IL1R2 antibody, an antigen binding fragment thereof and the use thereof, which belong to the field of biotechnology. The present invention relates to a monoclonal antibody. In addition, further provided are a phage displaying the monoclonal antibody on the surface, a method for preparing the monoclonal antibody and a pharmaceutical composition containing the monoclonal antibody. The monoclonal antibody can specifically bind to an IL1R2 protein, especially human and mouse IL1R2 proteins, and has a good inhibitory effect on the growth of tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Anti-IL1R2 antibodies, antigen-binding fragments thereof and applications Technical Field The invention relates to an anti-IL1R2 antibody, an antigen binding fragment thereof and application thereof, and belongs to the field of biotechnology. Background Art Regulatory T cells (Treg) are a type of T cell subset that has significant immunosuppressive effects and is characterized by the expression of Foxp3, CD25, and CD4. [1] Treg cells can negatively regulate the body's immune response through cell-to-cell contact and secretion of inhibitory cytokines in various immune cell subsets, inhibiting the body's immune response and tolerance to self-antigens, thereby avoiding the occurrence of autoimmune diseases. [2-4] Similarly, in some tumors, through immunosuppression, Treg cells make the body produce antigen tolerance to tumor cells, which will cause tumor cells to escape immune system, indirectly accelerate tumor cell proliferation, and enhance tumor cell infiltration ability. [5] Therefore, in tumor treatment, it is crucial to reduce the function of Treg cells. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) highly expressed on the surface of Treg cells is believed to enable them to competitively bind to B7 expressed by antigen presenting cells (APC), thereby preventing them from stimulating naive T cells. [6,7] . In fact, it has been proposed that CTLA-4 expressed on Treg can physically remove B7 molecules from the surface of APC, thereby eliminating their co-stimulatory activity. Therefore, many pharmaceutical companies have developed inhibitors against CTLA-4. In 2011, the U.S. Food and Drug Administration (FDA) approved BMS's Ipilimumab, commonly known as Y drug, which is the world's first immune checkpoint inhibitor and the only anti-CTLA-4 monoclonal antibody currently on the market. [8] As the research progresses, researchers believe that CTLA-4 inhibitors do not exert their anti-tumor effects by blocking the interaction between CTLA-4 and B7, but rather through the antibody-dependent cell-mediated cytotoxicity (ADCC) effect mediated by the antibody Fc receptor, effectively eliminating Tregs that highly express CTLA-4 and infiltrate tumor tissues, thereby eliminating the immunosuppressive effect of Tregs and achieving anti-tumor effects. [7] . Although immune checkpoint inhibitors (ICI) therapy represented by CTLA-4 are an important means of tumor immunotherapy and have significant clinical efficacy, due to the immunosuppression of the malignant tumor microenvironment (TME), the overall remission rate of ICI is low and the side effects are extremely large. Therefore, the development of new targets has become particularly important. [9] . Interleukin 1 receptor type II (IL1R2), also known as CD121b (cluster of Differentiation 121b), is a member of the interleukin 1 receptor family (IL-1R), which includes 10 receptors. Soluble proteins with similar structures [10,11] IL1R2 binds to IL1 and inhibits its interaction with activated IL1R1, so IL1R2 is considered to be a decoy receptor, thereby neutralizing the pro-inflammatory function of IL1 [10,11] A large number of studies have shown that IL1R2 is highly expressed on the cell membrane of Treg cells, but + Not expressed on conventional T cells (Tconv) [12,13] In addition, IL1R2 is highly expressed in tumor-infiltrating Treg cells in human breast cancer, colorectal cancer, and lung cancer. Therefore, it is possible to develop antibodies against IL1R2 to enhance the body's anti-tumor immunity. Summary of the invention Problem that the invention aims to solve Current studies have shown that although Tregs play an important role in maintaining peripheral tolerance and preventing autoimmunity, they also inhibit the anti-tumor immune effect in the tumor microenvironment. Therefore, inhibiting or eliminating the function or number of Treg cells infiltrating the tumor microenvironment becomes crucial for anti-tumor immunotherapy. As a target of Treg cells, CTLA-4 targeted inhibitors can not only promote the production of more immune cells, but also eliminate Treg cells infiltrating tumor tissues, playing an immune enhancement role.

[0016] Although monoclonal antibody drugs targeting CTLA-4 molecules have shown a better overall survival rate in clinical trials and have significantly improved clinical efficacy compared with the control group, these antibody drugs often have side effects such as rash, diarrhea, fatigue, itching, headache, weight loss and nausea during clinical use. Some patients may even die due to over-activation of the immune system.

[0017] Therefore, it is necessary to find new targets for Treg cells in order to make up for the defects of CTLA-4 inhibitors. Solutions for solving problems Phage display technology is a biotechnology that inserts the DNA sequence of foreign proteins or polypeptides into the appropriate position of the structural gene of the phage coat protein, so that the foreign gene is expressed along with the expression of the coat protein, and the foreign protein is displayed on the surface of the phage along with the reassembly of the phage. [14,15] In the present disclosure, a phage human antibody library is constructed using human scFV, and specific antibodies against IL1R2 are screened by specifically binding to human IL1R2 protein, and the anti-tumor effect of the antibodies is evaluated. The technical solution of the present disclosure is as follows: [1] An anti-IL1R2 antibody or an antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, wherein: The light chain variable region comprises LCDR1, LCDR2 and LCDR3 selected from any one of the following (a1) to (a4): (a1) LCDR1 as shown in SEQ ID NO:9, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO:10; (a2) LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO: 12; (a3) LCDR1 as shown in SEQ ID NO: 13, LCDR2 as shown in sequence KVS, and LCDR3 as shown in SEQ ID NO: 14; or (a4) LCDR1 as shown in SEQ ID NO: 15, LCDR2 as shown in sequence GNS, and LCDR3 as shown in SEQ ID NO: 16; The heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 selected from any one of the following (b1) to (b4): (b1) HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, and HCDR3 as shown in SEQ ID NO: 19; (b2) HCDR1 as shown in SEQ ID NO:20, HCDR2 as shown in SEQ ID NO:21, and HCDR3 as shown in SEQ ID NO:22; (b3) HCDR1 as shown in SEQ ID NO:23, HCDR2 as shown in SEQ ID NO:24, and HCDR3 as shown in SEQ ID NO:25; or (b4) HCDR1 as shown in SEQ ID NO:26, HCDR2 as shown in SEQ ID NO:27 and HCDR3 as shown in SEQ ID NO:28. [2] The anti-IL1R2 antibody or antigen-binding fragment thereof according to [1], comprising a heavy chain variable region as shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7; and / or, It comprises a light chain variable region as shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8. [3] The anti-IL1R2 antibody or antigen-binding fragment thereof according to [1] or [2], wherein the anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a heavy chain constant region derived from human IgG1, IgG2, IgG3 or IgG4 or a variant thereof; and / or, The anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a light chain constant region derived from a human κ chain, λ chain or a variant thereof. [4] The anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of [1] to [3], wherein the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a human antibody; and / or, The anti-IL1R2 antibody or antigen-binding fragment thereof is selected from at least one of a full-length antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a single-chain antibody, and a multispecific antibody. [5]. An isolated polynucleotide, wherein the polynucleotide encodes the anti-IL1R2 protein according to any one of [1] to [4]. Antibodies or antigen-binding fragments thereof. [6]. An expression cassette, wherein the expression cassette comprises the polynucleotide described in [5]. [7]. A recombinant vector, wherein the recombinant vector comprises the polynucleotide described in [5] or the expression cassette described in [6]. [8]. A host cell, wherein the host cell comprises the polynucleotide described in [5], the expression cassette described in [6], or the recombinant vector described in [7]. [9] The host cell according to [8], wherein the host cell is a microorganism or a mammalian cell; Optionally, the microorganism is selected from bacteria and / or yeast; Optionally, the mammalian cells are selected from HEK293T cells, HEK293F cells, HEK293 cells and / or CHO cells.

[0010] . A phage, wherein the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of [1] to [4] is displayed on the surface of the phage.

[0011] A method for preparing an anti-IL1R2 antibody or an antigen-binding fragment thereof as described in any one of [1] to [4], comprising culturing the host cell as described in [8] or [9] under conditions that allow the production of the anti-IL1R2 antibody or the antigen-binding fragment thereof, and recovering and isolating the anti-IL1R2 antibody or the antigen-binding fragment thereof.

[0012] A pharmaceutical composition comprising: the anti-IL1R2 antibody or antigen-binding fragment thereof as described in any one of [1] to [4], the polynucleotide as described in [5], the expression cassette as described in [6], the recombinant vector as described in [7], or the host cell as described in [8] or [9]; and Optionally, pharmaceutically acceptable carriers and / or excipients.

[0013] . Use of an anti-IL1R2 antibody or antigen-binding fragment thereof as described in any one of [1] to [4], a polynucleotide as described in [5], an expression cassette as described in [6], a recombinant vector as described in [7], a host cell as described in [8] or [9], or a pharmaceutical composition as described in

[0012] in the preparation of a medicament for treating an IL1R2-mediated disease or condition. Effects of the Invention The present invention uses phage display technology to screen out four clones, 3999-R3P1-B1, 3999-R3P1-H1, 3999-R3P1-E4 and 3999-R3P1-E11, and purifies the antibodies for antibody expression. The purified antibodies are subjected to SDS-PAGE qualitative and quantitative analysis, and quality control is performed at the same time. The purified antibodies are then subjected to ELISA experiments. (1) In one embodiment, the antibodies obtained in the present disclosure have good binding ability to human IL1R2 protein, and can also bind to mouse IL1R2 protein. (2) In another embodiment, the antibodies obtained in the present disclosure can effectively inhibit the growth of mouse tumors and improve the overall survival rate of mice. At the same time, it also provides new targets and new research directions for tumor immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a Coomassie blue staining of the purified antibody; MW: protein standard (unit: kDa), lanes 1 to 4 are 3999-R3P1-B1, 3999-R3P1-H1, 3999-R3P1-E4 and 3999-R3P1-E11, respectively. FIG. 2 is a graph showing the results of an ELISA experiment for screening antibodies. FIG3 is a graph showing the tumor growth curve of mice after three injections of antibodies. FIG. 4 is a graph showing the tumor growth curve of mice after 6 injections of antibodies. FIG5 is a survival curve of mice. FIG6 is a Coomassie brilliant blue staining image of IL1R2 protein; MW: protein standard (unit: kDa). DETAILED DESCRIPTION Various exemplary embodiments, features and aspects of the present invention will be described in detail below. The word "exemplary" used here means "used as an example, embodiment or illustrative". Any embodiment described here as "exemplary" is not necessarily interpreted as being superior or better than other embodiments. In addition, in order to better illustrate the present invention, numerous specific details are provided in the following specific embodiments. It should be understood by those skilled in the art that the present invention can be implemented without certain specific details. In other examples, methods, means, equipment and steps well known to those skilled in the art are not described in detail in order to highlight the subject matter of the present invention. Unless otherwise stated, the units used in this specification are all international standard units, and the numerical values ​​and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production. In this specification, the word "may" includes both performing a certain process and not performing a certain process. In this specification, the references to "some specific / preferred embodiments", "other specific / preferred embodiments", "embodiments", etc., mean that the specific elements (e.g., features, structures, properties and / or characteristics) described in connection with the embodiments are included in at least one embodiment described herein, and may or may not exist in other embodiments. In addition, it should be understood that the elements may be combined in various embodiments in any suitable manner. In this specification, the numerical range expressed by "a numerical value A to a numerical value B" means a range including the endpoints A and B. Surround. In the present specification, the use of “substantially” or “essentially” means that the standard deviation from a theoretical model or theoretical data is within a range of 5%, preferably 3%, and more preferably 1%. In the present specification, "optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes cases where the event occurs and cases where it does not occur. In this specification, when the term "and / or" is used to connect two or more options, it should be understood to mean any one of the options or any two or more of the options. In this specification, the term "interleukin 1 receptor type II" or "IL12R" is a decoy receptor that neutralizes interleukin-1 (IL1), which has three immunoglobulin extracellular domains and a bolt transmembrane region, can capture and isolate IL-1, thereby blocking the IL-1 signaling pathway and negatively regulating IL-1. It is mainly expressed on neutrophils, B cells, monocytes and macrophages, and can also be induced on keratinocytes and endothelial cells. In the present disclosure, the terms "polypeptide", "protein" and "peptide" are used interchangeably herein to refer to a polymeric form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides with similar peptide backbones. In this disclosure, the terms "nucleic acid molecule", "polynucleotide", "polynucleic acid", and "nucleic acid" are used interchangeably to refer to a polymeric form of nucleotides of any length, whether deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides can have any three-dimensional structure and can perform any known or unknown function. Non-limiting examples of polynucleotides include genes, gene fragments, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, control regions, isolated RNA of any sequence, nucleic acid probes, and primers. Nucleic acid molecules can be linear or circular. In this disclosure, the three letter codes and one letter codes for amino acids used are as described in J. biol. chem, 243, p3558 (1968). In the present disclosure, the term "antibody" described in the present disclosure refers to immunoglobulin, which is a tetrapeptide chain structure composed of two identical heavy chains and two identical light chains connected by interchain disulfide bonds. The amino acid composition and arrangement order of the constant region of the immunoglobulin heavy chain are different, so its antigenicity is also different. Based on this, immunoglobulins can be divided into five categories, or isotypes of immunoglobulins, namely IgM, IgD, IgG, IgA and IgE, and their corresponding heavy chains are μ chain, δ chain, γ chain, α chain and ε chain, respectively. The same class of Ig can be divided into different subclasses according to the difference in the amino acid composition of its hinge region and the number and position of the heavy chain disulfide bonds, such as IgG can be divided into IgG1, IgG2, IgG3, and IgG4. The light chain is divided into κ chain or λ chain by the difference in the constant region. Each of the five types of Ig can have a κ chain or a λ chain. In the present disclosure, the antibody light chain may further comprise a light chain constant region, wherein the light chain constant region comprises a human or murine κ, λ chain or a variant thereof. In the present disclosure, the antibody heavy chain may further comprise a heavy chain constant region, wherein the heavy chain constant region comprises human or murine IgG1, IgG2, IgG3, IgG4 or variants thereof. The sequences of about 110 amino acids near the N-terminus of the antibody heavy and light chains vary greatly, which is the variable region (V region); the remaining amino acid sequences near the C-terminus are relatively stable, which is the constant region (C region). The variable region includes three hypervariable regions (HVRs) and four framework regions (FRs) with relatively conservative sequences. The three hypervariable regions determine the specificity of the antibody, also known as the complementary determining regions (CDRs). Each light chain variable region (VL) and heavy chain variable region (VH) consists of three CDR regions and four FR regions, arranged in the order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The three CDR regions of the light chain refer to CDRL1, CDRL2, and CDRL3; the three CDR regions of the heavy chain refer to CDRH1, CDRH2, and CDRH3. In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including, for example: Chothia based on the three-dimensional structure of the antibody and the topology of the CDR loops (Chothia et al. (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics database (IMGT) (on the World Wide Web at imgt.cines.fr / ), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures. The number and position of the CDR amino acid residues in the VL and VH regions of the antibody or antigen-binding fragment conform to the known Kabat numbering convention and the Kabat or AbM or IMGT definition conventions (http: / / bioinf.org.uk / abs / ).In some specific embodiments of the present disclosure, the CDR amino acid residues in the VL region and VH region of the antibody or antigen-binding fragment are determined according to the IMGT definition rules. The term "human antibody" or "humanized antibody" includes antibodies having variable and constant regions of human germline immunoglobulin sequences. The human antibodies of the invention may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). In the present disclosure, the term "antigen binding fragment" refers to an antigen binding fragment of an antibody and an antibody analog, which generally includes at least a portion of the antigen binding region or variable region (e.g., one or more CDRs) of a parental antibody. Antibody fragments retain at least some of the binding specificity of the parental antibody. Typically, when activity is expressed on a molar basis, antibody fragments retain at least 10% of the parental binding activity. Preferably, antibody fragments retain at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the binding affinity of the parental antibody to the target. Examples of antigen binding fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, linear antibodies, single-chain antibodies, domain antibodies, single-domain antibodies or nanobodies, and multispecific antibodies. Engineered antibody variants are reviewed in Holliger and Hudson, 2005, Nat.Biotechnol.23:1126-1136. The term "Fab fragment" comprises a light chain and the CH1 and variable region of a heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. The term "Fab' fragment" contains one light chain and a portion or fragment of one heavy chain, said portion or fragment containing the VH domain and the CH1 domain and the region between the CH1 and CH2 domains. The term "F(ab')2 fragment" contains two light chains and two heavy chains, wherein the heavy chain contains a portion of the constant region between the CH1 and CH2 domains, so that an interchain disulfide bond is formed between the two heavy chains. The F(ab')2 fragment is thus composed of two Fab' fragments, which are linked together by a disulfide bond between the two heavy chains. The term "Fv fragment" comprises the variable regions from the heavy and light chains, but lacks the constant regions. In the present disclosure, the term "single-chain antibody", "single-chain Fv" or "scFv", i.e. "single-chain variable region fragment", is an antibody fragment composed of the variable region of the antibody heavy chain and the variable region of the light chain through a short peptide of 15-20 amino acids, wherein these domains exist in the form of a single polypeptide chain, and are small molecule genetically engineered antibodies. The term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and the antigen to which it is directed. The term "immunological binding" refers to a specific binding reaction occurring between an antibody molecule and an antigen (for which the antibody is specific). The strength or affinity of the immune binding interaction can be expressed by the equilibrium dissociation constant (KD) of the interaction, wherein the smaller the KD value, the higher the affinity. The immune binding properties between two molecules can be quantified using methods known in the art. One method involves measuring the speed of formation and dissociation of antigen binding sites / antigen complexes. The "association rate constant" (Ka or Kon) and "dissociation rate constant" (Kd or Koff) referring to a specific antibody-antigen interaction can both be calculated by the actual rate of concentration and association and dissociation, see Malmqvist M, 1993, Nature, 361: 186-187. The ratio of Kd / Ka is equal to the dissociation constant KD, see Davies DR et al., 1990, Annual Rev Biochem., 59: 439-473. KD, Ka and Kd values ​​may be measured by any effective method. In a preferred embodiment, the dissociation constant is measured using bioluminescence interferometry. In other preferred embodiments, the dissociation constant may be measured using surface plasmon resonance technology (e.g., Biacore) or KinExa. The term "phage display library" refers to a "library" of phages on which exogenous peptides or proteins are expressed on their surfaces. Foreign peptides or polypeptides are displayed on the outer surface of the phage capsid. Foreign peptides can be displayed as recombinant fusion proteins incorporated as part of a phage coat protein; recombinant fusion proteins that are usually not phage coat proteins, but can become incorporated into the outer surface of the capsid; or proteins or peptides that become covalently or non-covalently linked to the protein. This is achieved by inserting an exogenous nucleic acid sequence into a nucleic acid that can be packaged into a phage particle. The exogenous nucleic acid sequence can, for example, be inserted into the coding sequence of a phage coat protein gene. If the foreign sequence is an in-frame clone, the protein it encodes will be expressed as part of the coat protein. Therefore, a library of nucleic acid sequences, such as a library of antibody repertoires made from gene segments encoding the entire B cell repertoire of one or more individuals, can be inserted into a phage to produce a "phage library". When peptides and proteins representing those encoded by a nucleic acid library are displayed by phage, a "peptide display library" is produced. Although a variety of phage are used in the construction of such libraries, filamentous phage are typically used. Bacteria (Dunn (1996) Curr. Opin. Biotechnol. 7: 547-553). Antibody libraries are generally divided into several categories, including naive antibody library, immune antibody library, synthetic antibody library, and semi-synthetic antibody library. The terms "individual", "patient" or "subject" used in the context of this disclosure include mammals. Mammals include, but are not limited to, domestic animals (e.g., cows, sheep, cats, dogs and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In the present disclosure, the term "antigen binding site" refers to the three-dimensional site recognized by the antibodies or antigen-binding fragments of the present disclosure. In the present disclosure, "identity" refers to the sequence similarity between two polynucleotide sequences or between two polypeptides. When the positions in the two compared sequences are occupied by the same base or amino acid monomer subunit, for example, if every position of the two DNA molecules is occupied by adenine, then the molecules are homologous at that position. The percent identity between two sequences is a function of the number of matching or homologous positions shared by the two sequences divided by the number of positions compared × 100%. For example, when the sequences are optimally aligned, if 6 out of 10 positions in the two sequences are matched or homologous, then the two sequences are 60% homologous. In general, the comparison is made when the two sequences are aligned to obtain the maximum percent identity. In the present disclosure, the term "expression cassette" is a recombinant expression element comprising a target gene and a regulatory element that regulates the expression of the target gene. In some embodiments, the target gene is a coding gene for a target polypeptide. In some embodiments, the regulatory element is a promoter element for initiating transcription of the coding gene. In some embodiments, the regulatory element may also include enhancers, silencers, insulators and other elements. In the present disclosure, "vector" refers to a vector comprising a recombinant polynucleotide, which includes an expression control sequence operably linked to a nucleotide sequence to be expressed. An expression vector includes cis-acting components sufficient for expression; other components for expression can be provided by a host cell or in an in vitro expression system. Expression vectors include all those known in the art, such as cosmids, plasmids (such as naked or contained in liposomes), and viruses (such as lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) that introduce recombinant polynucleotides. In this disclosure, the terms "cell," "cell line," and "cell culture" are used interchangeably, and all such designations include progeny. Thus, the terms "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, without regard to the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or unintentional mutations. Mutant progeny that have the same function or biological activity as screened for in the originally transformed cell are included. In the present disclosure, the term "host cell" refers to a cell into which an expression vector has been introduced. The host cell of the present invention can be bacteria, microorganisms, plants or animal cells. Bacteria that are easily transformed include members of the family Enterobacteriaceae, such as strains of Escherichia coli or Salmonella; Bacillaceae, such as Bacillus subtilis; Pneumococcus; Streptococcus and Haemophilus influenzae. Suitable microorganisms include Saccharomyces cerevisiae and Pichia pastoris. Suitable animal host cell lines include CHO (Chinese Hamster Ovary Cell Line) and NS0 cells. "Administering," "giving," and "treating" when applied to an animal, a human, an experimental subject, a cell, a tissue, an organ, or a biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent, or composition with an animal, a human, a subject, a cell, a tissue, an organ, or a biological fluid. "Administering," "giving," and "treating" may refer to, for example, treatment, pharmacokinetics, diagnosis, research, and experimental procedures. Treatment of cells includes contact of an agent with a cell, and contact of an agent with a fluid, wherein the fluid is in contact with the cell. "Administering," "giving," and "treating" also mean in vitro and ex vivo treatment of, for example, a cell, by an agent, a diagnostic agent, a binding composition, or by another cell. "Treatment," when applied to humans, veterinary medicine, or a research subject, refers to therapeutic, prophylactic or preventative measures, research, and diagnostic applications. "Treatment" means administering an internal or external therapeutic agent, such as any of the antibodies disclosed herein, to a patient who has one or more symptoms of a disease for which the therapeutic agent is known to have a therapeutic effect. Typically, the therapeutic agent is administered in an amount effective to alleviate one or more symptoms of a disease in the patient or population being treated, whether by inducing regression of such symptoms or inhibiting the development of such symptoms to any clinically measurable degree. The amount of a therapeutic agent effective to alleviate any specific disease symptom (also referred to as a "therapeutically effective amount") may vary according to a variety of factors, such as the patient's disease state, age, and weight, and the ability of the drug to produce the desired therapeutic effect in the patient. Whether a disease symptom has been alleviated may be evaluated by any clinical test method commonly used by a physician or other health care professional to evaluate the severity or progression of the symptom. The term "diagnosis" includes the detection or identification of a disease state or condition in a subject, determining the likelihood that a subject will develop a given disease or condition, determining the likelihood that a subject with a disease or condition will respond to treatment, determining the prognosis of a subject with a disease or condition (or its likely progression or regression), and determining the effectiveness of treatment for a subject with a disease or condition. In the present disclosure, an "effective amount" includes an amount sufficient to improve or prevent the symptoms or conditions of a medical condition. An effective amount also means an amount sufficient to allow or facilitate diagnosis. The effective amount for a particular patient or veterinary subject may vary depending on factors such as the condition to be treated, the patient's overall health, the method, route and dosage of administration, and the severity of side effects. An effective amount can be the maximum dose or dosage regimen that avoids significant side effects or toxic effects. In this disclosure, a "therapeutically effective amount" is an amount sufficient to provide a therapeutic benefit in the treatment of a condition or sufficient to delay or minimize one or more symptoms associated with the condition. A therapeutically effective amount refers to a therapeutic agent alone or in combination with other therapies. The term "therapeutically effective amount" can include an amount that improves overall therapy; reduces or avoids symptoms, signs, or causes of a disorder; and / or enhances the therapeutic efficacy of another therapeutic agent. In the present disclosure, a "prophylactically effective amount" is an amount sufficient to prevent a condition or one or more symptoms associated with a condition or to prevent its recurrence. A prophylactically effective amount refers to an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in preventing a condition. The term "prophylactically effective amount" may include an amount that improves overall prevention or enhances the prophylactic efficacy of another prophylactic agent. The term "subject" refers to a human (i.e., a male or female of any age, e.g., a pediatric subject (e.g., an infant, child, or adolescent) or an adult subject (e.g., a young, middle-aged, or elderly person)) or a non-human animal. In certain embodiments, the non-human animal is a mammal (e.g., a primate (e.g., a cynomolgus monkey or a rhesus monkey), a commercially relevant mammal (e.g., a cow, pig, horse, sheep, goat, cat, or dog), or a bird. The non-human animal can be male or female at any stage of development. The non-human animal can be a transgenic animal or a genetically engineered animal. "Pharmaceutical composition" means containing one or more antibodies described herein, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitate the absorption of the active ingredient, and thus exert biological activity. In the present disclosure, the term "pharmaceutically acceptable" (or "pharmacologically acceptable") refers to molecular entities and compositions that do not produce adverse reactions, allergic reactions or other untoward reactions when administered to animals or humans, as appropriate. <Anti-IL1R2 Antibody or Antigen-binding Fragment thereof> Treg cells are an important component of tumor immune tolerance. Studies have shown that IL1R2 (CD121b) is highly expressed in Treg cells in the tumor microenvironment. Therefore, IL1R2 has become a potential new intervention target in tumor immunotherapy. Phage antibody library technology can be used to screen B cell antibody libraries of humans and other animals in vitro, avoiding the steps of immunization and cell fusion, thereby shortening the experimental cycle and increasing stability, and achieving the screening of fully human antibody sequences with high affinity in a short period of time. In the present disclosure, a phage human antibody library was constructed and a human anti-IL1R2 antigen monoclonal antibody was screened. The first aspect of the present disclosure provides an anti-IL1R2 antibody or an antigen-binding fragment thereof, which comprises a light chain variable region and a heavy chain variable region, wherein: The light chain variable region comprises LCDR1, LCDR2 and LCDR3 selected from any one of the following (a1) to (a4): (a1) LCDR1 as shown in SEQ ID NO:9, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO:10; (a2) LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO: 12; (a3) LCDR1 as shown in SEQ ID NO: 13, LCDR2 as shown in sequence KVS, and LCDR3 as shown in SEQ ID NO: 14; or (a4) LCDR1 as shown in SEQ ID NO: 15, LCDR2 as shown in sequence GNS, and LCDR3 as shown in SEQ ID NO: 16; The heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 selected from any one of the following (b1) to (b4): (b1) HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, and HCDR3 as shown in SEQ ID NO: 19; (b2) HCDR1 as shown in SEQ ID NO:20, HCDR2 as shown in SEQ ID NO:21, and HCDR3 as shown in SEQ ID NO:22; (b3) HCDR1 as shown in SEQ ID NO:23, HCDR2 as shown in SEQ ID NO:24, and HCDR3 as shown in SEQ ID NO:25; or (b4) HCDR1 as shown in SEQ ID NO:26, HCDR2 as shown in SEQ ID NO:27 and HCDR3 as shown in SEQ ID NO:28. In some specific embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises (a1) LCDR1 as shown in SEQ ID NO:9, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO:10; the heavy chain variable region comprises (b1) HCDR1 as shown in SEQ ID NO:17, HCDR2 as shown in SEQ ID NO:18, and HCDR3 as shown in SEQ ID NO:19; and / or, The light chain variable region comprises (a2) LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in sequence RNN and LCDR3 as shown in SEQ ID NO: 12; the heavy chain variable region comprises (b2) HCDR1 as shown in SEQ ID NO: 20, HCDR2 as shown in SEQ ID NO: 21 and HCDR3 as shown in SEQ ID NO: 22; and / or, The light chain variable region comprises (a3) ​​LCDR1 as shown in SEQ ID NO: 13, LCDR2 as shown in sequence KVS, and LCDR3 as shown in SEQ ID NO: 14; the heavy chain variable region comprises (b3) HCDR1 as shown in SEQ ID NO: 23, HCDR2 as shown in SEQ ID NO: 24, and HCDR3 as shown in SEQ ID NO: 25; and / or, The light chain variable region comprises (a4) LCDR1 as shown in SEQ ID NO: 15, LCDR2 as shown in sequence GNS, and LCDR3 as shown in SEQ ID NO: 16; the heavy chain variable region comprises (b4) HCDR1 as shown in SEQ ID NO: 26, HCDR2 as shown in SEQ ID NO: 27, and LCDR3 as shown in SEQ ID NO: 28. HCDR3. In some embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7; and / or, it comprises a light chain variable region as shown in SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6 or SEQ ID NO: 8. In some specific embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO:1 and a light chain variable region as shown in SEQ ID NO:2. In some specific embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO:3 and a light chain variable region as shown in SEQ ID NO:4. In some specific embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO:5 and a light chain variable region as shown in SEQ ID NO:6. In some specific embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a heavy chain variable region as shown in SEQ ID NO:7 and a light chain variable region as shown in SEQ ID NO:8. In some embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a heavy chain constant region derived from human IgG1, IgG2, IgG3 or IgG4 or a variant thereof; and / or, the anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a light chain constant region derived from human κ chain, λ chain or a variant thereof. In some specific embodiments, the heavy chain constant region sequence is shown as SEQ ID NO:37, and the light chain constant region sequence is shown as SEQ ID NO:38. In some embodiments, the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a human antibody; and / or the anti-IL1R2 antibody or antigen-binding fragment thereof is selected from at least one of a full-length antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a single-chain antibody, and a multispecific antibody. In addition, other amino acid sequences that do not substantially affect the activity, expression level and stability of the anti-IL1R2 antibody or antigen-binding fragment thereof of the present invention may be added to the amino or carboxyl terminus of the anti-IL1R2 antibody or antigen-binding fragment thereof. Preferably, these added amino acid sequences are conducive to expression (such as signal peptides), purification (such as 6×His sequences), or other sequences that can promote the activity, expression level or stability of the anti-IL1R2 antibody or antigen-binding fragment thereof. Furthermore, in order to further increase the expression level of the host cell, the coding sequence of the antibody of the present invention can be modified. Modifications can be made, such as using codons preferred by the host cell and eliminating sequences that are not conducive to gene transcription and translation. In some embodiments, after obtaining the DNA sequence encoding the anti-IL1R2 antibody or antigen-binding fragment thereof of the present disclosure, it is cloned into a suitable expression vector and then transferred into a suitable host cell. Finally, the transformed host cell is cultured and the anti-IL1R2 antibody or antigen-binding fragment thereof of the present disclosure is obtained by separation and purification. <Polynucleotide> The present disclosure provides an isolated polynucleotide encoding the above-mentioned anti-IL1R2 antibody or antigen-binding fragment thereof. In some embodiments, polynucleotide can be in DNA form or RNA form.DNA form includes cDNA, genomic DNA or artificially synthesized DNA.DNA can be single-stranded or double-stranded, preferably double-stranded DNA.DNA can be a coding strand or a non-coding strand.Unless otherwise indicated, specific polynucleotide sequence also implicitly encompasses conservatively modified variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs and complementary sequences and sequences explicitly indicated. <Expression cassette, recombinant vector, host cell> Based on the polynucleotide obtained by the present disclosure, the present disclosure provides an expression cassette comprising the polynucleotide as described in the present disclosure. In other embodiments, the present disclosure provides a recombinant vector comprising a polynucleotide or expression cassette as described in the present disclosure. In other embodiments, the present disclosure provides a host cell comprising a polynucleotide, expression cassette or recombinant vector as described in the present disclosure. In some specific embodiments, the host cell is a bacterium; illustratively, the host cell is Escherichia coli or Bacillus subtilis, but is not limited thereto. In other specific embodiments, the host cell is a yeast, illustratively, the host cell is Pichia pastoris or Saccharomyces cerevisiae, but not limited thereto. In other specific embodiments, the host cell is a mammalian cell. Exemplarily, the host cell is a mammalian cell line, such as HEK293T cells, HEK293F cells, HEK293 cells, CHO cells, but not limited thereto. <Bacteriophage> The present disclosure provides a phage, on the surface of which the above-mentioned anti-IL1R2 antibody or antigen-binding fragment thereof is displayed. In some embodiments, phage display technology is used when constructing a human scFv antibody library to display foreign proteins. The DNA sequence of the polypeptide is incorporated into the appropriate position of the structural gene of the phage coat protein, so that the foreign gene is expressed along with the expression of the coat protein. At the same time, the foreign protein is displayed on the phage surface along with the reassembly of the phage. <Pharmaceutical Composition> The present disclosure provides a pharmaceutical composition, which includes the above-mentioned anti-IL1R2 antibody or antigen-binding fragment thereof, polynucleotide, expression cassette, recombinant vector or host cell. Furthermore, the pharmaceutical composition may also include a pharmaceutically acceptable carrier and / or excipient. In some embodiments, the pharmaceutically acceptable carrier and / or excipient are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995). These substances are used to help the stability of the formulation or to help improve the bioavailability of the active substance or to produce an acceptable taste or smell in the case of oral administration. The pharmaceutical composition prepared in this way can be administered in any appropriate manner known to those skilled in the art as needed. In some embodiments, the pharmaceutical composition can be prepared into any conventional pharmaceutical dosage form. <Therapeutic Uses> The present disclosure provides use of the anti-IL1R2 antibody or antigen-binding fragment thereof, polynucleotide, expression cassette, recombinant vector, host cell, or pharmaceutical composition described in the present disclosure in the preparation of a medicament for treating a disease or condition mediated by IL1R2. In some embodiments, the IL1R2-mediated disease or condition includes urothelial carcinoma, prostate cancer, cervical cancer, endometrial cancer, ovarian cancer, breast cancer, colorectal cancer, pancreatic cancer, skin cancer, non-small cell lung cancer, osteosarcoma, lymphoma, liver cancer, adrenocortical carcinoma, etc. <Treatment Method> The present disclosure provides an anti-IL1R2 antibody or antigen-binding fragment thereof, a polynucleotide, an expression cassette, a recombinant vector, a host cell or a pharmaceutical composition as described in the present disclosure, for use in preventing and / or treating a disease or condition mediated by IL1R2. The present disclosure provides a method for preventing and / or treating IL1R2-mediated diseases or conditions, comprising administering to a subject a preventively or therapeutically effective amount of an anti-IL1R2 antibody or antigen-binding fragment thereof, a polynucleotide, an expression cassette, a recombinant vector, a host cell or a pharmaceutical composition as described in the present disclosure. In some embodiments, the IL1R2-mediated disease or condition includes urothelial carcinoma, prostate cancer, cervical cancer, endometrial cancer, ovarian cancer, breast cancer, colorectal cancer, pancreatic cancer, skin cancer, non-small cell lung cancer, osteosarcoma, lymphoma, liver cancer, adrenocortical carcinoma, etc. Example The embodiments of the present invention will be described in detail below with reference to the examples, but those skilled in the art will appreciate that It is understood that the following examples are only used to illustrate the present invention and should not be considered to limit the scope of the present invention. If specific conditions are not specified in the examples, they are carried out according to conventional conditions or conditions recommended by the manufacturer. If the manufacturer of the reagents or instruments used is not specified, they are all conventional products that can be obtained commercially. Embodiment 1 1. Screening and synthesis of antibodies (1) Construction of a humanized phage display antibody library in the form of human scFv ① Using the cDNA obtained by reverse transcription of human lymphocyte RNA as a template, PCR amplified the antibody variable region sequence, including the heavy chain variable region VH and the light chain variable region VL; after 1% agarose gel electrophoresis, the target fragment of 300-500bp was recovered. ② The heavy chain variable region and the light chain variable region were connected by overlapping extension PCR method with a connecting peptide linker (GGGGSGGGGSGGGGSGGGGAS, SEQ ID NO: 41); the target fragment of 700-800 bp was recovered by gel. ③ The recovered target fragment and vector pCANTAB5E (Amersham biosciences) were digested with SfiI (Company: Thermo Scientific, Catalog No.: FD1824) and NotI (Company: Thermo Scientific, Catalog No.: FD0595), and then ligated overnight at 16°C under the action of T4 ligase (Company: NEB, Catalog No.: M0202S); the ligation product was transferred into TG1 electrotransformation competent cells (Company: Lucigen, Catalog No.: 60502) by electrotransformation, and plated on 2YT-Amp-Glucose (2×YT medium with 2% glucose and 100ug / ml ampicillin) solid culture medium (the formula is the same as below), and cultured overnight at 37°C; ④ Scrape the colonies on the culture medium, mix them evenly, take part of the bacterial solution, inoculate it into 2×YT-Amp-Glucose culture medium, and culture at 37℃ until OD 600 =0.4-0.6; add helper phage, culture at 37℃ for 1h; centrifuge the bacterial solution at 5000rpm, discard the supernatant, and resuspend with an equal volume of 2YT-Amp-Kan medium (2×YT medium with 50ug / ml kanamycin and 100ug / ml ampicillin); culture overnight at 30℃; the next day, centrifuge and take the supernatant; add 1 / 4 volume of 5×PEG / NaCl solution to the supernatant, mix well, and place on ice for 1-2h; centrifuge and discard the supernatant, resuspend the precipitate with PBS, and finally obtain the single-chain ScFv phage library. Store at 20℃; Primers required for library construction: Heavy chain amplification primers: 5'L-VH 1: ACAGGTGCCCACTCCCAGGTGCAG (SEQ ID NO: 42), 5′L-VH 3: AAGGTGTCCAGTGTGARGTGCAG (SEQ ID NO: 43), 5′L-VH 4 / 6: CCCAGATGGGTCCTGTCCCAGGTGCAG (SEQ ID NO: 44), 5'L-VH 5 / 7: CAAGGAGTCTGTTCCGAGGTGCAG (SEQ ID NO: 45), Reverse Primer: VH_R1:ACTCGAGACGGTGACCAGGGTGCC(SEQ ID NO:46), VH_R2:ACTCGAGACGGTGACCAGGGTTCC(SEQ ID NO:47); Kappa light chain amplification primers: 5′L VK 1 / 2: ATGAGGSTCCCYGCTCAGCTGCTGG (SEQ ID NO: 48), 5′L VK 3: CTCTTCCTCCTGCTACTCTGGCTCCCAG (SEQ ID NO:49), 5′L VK 4 / 5: ATTTCTCTGTTGCTCTGGATCTCTG (SEQ ID NO:50), 3′CK: TGCTGTCCTTGCTGTCCTGCT (SEQ ID NO: 51); Lambda light chain amplification primers: 5′L Vλ1:GGTCCTGGGCCCAGTCTGTGCTG (SEQ ID NO:52), 5'L Vλ2: GGTCCTGGGCCCAGTCTGCCCTG (SEQ ID NO: 53), 5'L Vλ3: GCTCTGTGACCTCCTATGAGCTG (SEQ ID NO: 54), 5'L Vλ4 / 5: GGTCTCTCTCSCAGCYTGTGCTG (SEQ ID NO: 55), 5'L Vλ6: GTTCTTGGGCCAATTTTATGCTG (SEQ ID NO: 56), 5'L Vλ7: GGTCCAATTCYCAGGCTGTGGTG (SEQ ID NO: 57), 5'L Vλ8 / 9 / 10: GAGTGGATTCTCAGACTGTGGTG (SEQ ID NO: 58), 3'Cλ: CACCAGTGTGGCCTTGTTGGCTTG (SEQ ID NO: 59). (2) The tubes were coated with 50 ug / mL of human IL1R2 protein (amino acid sequence as shown in SEQ ID NO: 39) (experimental group) and 0 ug / mL of IL1R2 protein (control group) and incubated at 4° C. in a shaking incubator overnight. The steps for synthesizing human IL1R2 protein are as follows: ① Introducing two restriction sites, EcoRI and NotI, at both ends of the human IL1R2 cDNA (SEQ ID NO: 40), and using these two enzymes for restriction digestion; ② The expression vector pATX2 (Company: ProteoGenix) was digested with EcoRI (Company: Thermo Scientific, Catalog No.: FD0274) and NotI (Company: Thermo Scientific, Catalog No.: FD0595) to linearize it; ③ Connect the fragments after enzyme digestion and the vector after enzyme digestion, and after transformation, obtain an expression vector carrying IL1R2 cDNA; ④ The vector was transfected into HEK293T for expression and purification, and then the IL1R2 protein was purified through the His tag and verified by SDS-PAGE. The results are shown in Figure 6. (3) Take out the tube coated in step (2) and wash it three times with 0.05% (v / v) PBST. (4) Add 5 mL of 5% skim milk or 1% (m / v) casein to the tube and block at 37°C for 2 h; Meanwhile, the phage library was diluted with 1% (m / v) milk or 0.2% (m / m) casein, and the diluted phage library was incubated at 25° C. for 2 h. (5) After the incubation, wash the tube sealed in step (4) once with 0.05% (v / v) PBST. (6) Place the diluted phage display library into the sealed tube in step (5) and incubate at 37°C for 2 h. (7) After incubation, the cells were washed three times with 0.05% PBST and then washed twice with PBS. (8) Elute the conjugate with 1 mL of glycine buffer solution (Glycine-HCl), and neutralize the eluate with Glycine-HCl until the pH reaches 7.0. 2. Phage titer detection (1) Culture E. coli TG1 (Company: Lucigen, Catalog No.: 60502) until OD 600 =0.4-0.6. (2) The liquid eluted in step (8) of the above “1. Screening and synthesis of antibodies” was diluted, and 10 μL of the diluted liquid was added to 180 μL of E. coli TG1 to obtain a culture. (3) The culture obtained in step (2) was cultured in a 37°C incubator for 30 minutes, then poured into a 2×YT-A (Amp 100 ug / mL) culture dish, spread evenly, and air-dried. The plate was inverted and cultured in a 37°C incubator overnight, and the titer of the eluted phage was determined. 3. Amplification of Eluted Phage (1) Take 10 μL of E. coli TG1 and add it to 800 μL of 2×YT liquid medium. Incubate in a shaker at 37°C until OD 600 =0.4-0.6. (2) TG1 cultured to the logarithmic phase was transferred to 10 mL of 2×YT-G liquid medium (final glucose concentration was 2%) and cultured on a shaker at 37°C until OD 600 =0.4-0.6. (3) The product eluted from step (8) in “1. Screening and synthesis of antibodies” was added to TG1 from step (2), incubated in a 37°C incubator for 30 minutes, and then shaken on a shaker at 37°C for 30 minutes. (4) Add 30 mL of 2×YT-AG liquid culture medium (final concentration of Amp is 0.1%, final concentration of glucose is 2%) to the system in step (3), and culture on a shaker at 37° C. for 1 h. (5) Add M13KO7 (company: NEB, catalog number: N0315S, M13KO7:TG1=20:1), incubate in a 37°C incubator for 30 min, and then shake on a shaker at 37°C for 30 min. (6) The bacterial solution obtained in step (5) was centrifuged at 5000 rpm for 5 minutes, the supernatant was discarded, and then resuspended with 40 mL of 2YT-AK and incubated on a shaker at 30°C overnight. (7) The culture obtained in step (6) was centrifuged, and the supernatant was transferred to a sterile tube. 1 / 5 (volume ratio) PEG / NaCl solution was added to the supernatant, and then mixed. The mixture was incubated on ice for 2 h. (8) Centrifuge the mixture after incubation on ice in step (7), resuspend the precipitate with 1 mL of PBS, centrifuge again, and then transfer the supernatant to a sterile tube. The substance in the sterile tube is the amplified phage, which can be used for the next bio-screening. 4. Detection and screening of amplified phage titers (1) Cultivate E. coli TG1 until OD 600 =0.4-0.6. (2) Dilute the amplified phage obtained in step (8) of the above "3. Amplification of eluted phage", and add 10 μL of the dilution to 180 μL of E. coli TG1. (3) Place the above culture in a 37°C incubator for 30 minutes, then pour it into a 2×YT-A (Amp 100ug / mL) culture dish, spread it evenly, and let it dry. Place the plate upside down in a 37°C incubator overnight. 5. Repeat the above steps until phages are screened out. Table 1 shows that ideal results can be obtained after three rounds of screening. Table 1. Screening results 6. Polyclonal phage ELISA detection (1) Coating: The test plate was coated with antigen (4 μg / ml IL1R2 protein in the experimental group and PBS in the control group) at 4°C overnight. (2) Washing: The antigen-coated plate was washed twice with 0.05% (v / v) PBST and then washed once with PBS. (3) Blocking: The plate was blocked with 300 μL of 5% skim milk at 30°C for 2 h. (4) Incubation: Add 100 μL of the amplified phage after gradient dilution and incubate at 37°C for 2 hours. (5) Washing: Wash the plate three times with 0.05% (v / v) PBST. (6) Secondary antibody incubation: Add diluted anti-M13-HRP antibody (Sino Biological, 11973-MM05T-H) (1:6000, diluted with blocking solution); add 100 μL to each well and incubate at 37°C for 1 hour. (7) Washing: Wash the plate three times with 0.05% (v / v) PBST. (8) Color development: Add 100 μL of TMB color development solution to each well and react at room temperature in the dark for 20 minutes; then add 100 μL of 2M HCl stop solution to each well to terminate the reaction. (9) Reading: Detect the absorbance at 450 nm on an ELISA reader. Table 2 shows the ELISA results of the polyclonal phage library. It can be seen from the table that after three rounds of panning, a relatively large number of phages can be obtained. For the ideal result. Table 2. Results of polyclonal phage ELISA assay (OD 450 ) Note: In Table 2, Ag is the experimental group and NC is the control group. 7. Monoclonal phage ELISA detection (1) Select 96 single colonies from the bacterial culture plate and culture them on a shaker at 37°C (250 rpm) until the OD 600 =0.4-0.6. (2) Infect the culture medium with M13KO7 (MOI = 20:1), incubate at 37°C for 30 minutes, and then shake on a shaker at 37°C for 30 minutes. Centrifuge, discard the supernatant, add an equal volume of 2×YT-AK medium (Amp 100 μg / mL, Kan 100 μg / mL), and culture overnight on a shaker at 37°C. (3) The culture medium obtained in step (2) is centrifuged and the supernatant can be used for ELISA detection. (4) Coating: The test plate was coated with antigen (4 μg / mL IL1R2 protein in the experimental group and PBS in the control group) at 4°C overnight. (5) Washing: The antigen-coated plate was washed twice with 0.05% (v / v) PBST and then washed once with PBS. (6) Blocking: The washed plate was blocked with 300 μL of 5% skim milk at 30°C for 2 h. (7) Incubation: Add 100 μL of the serially diluted amplified phage to the blocked plate and incubate at 37°C for 2 h. (8) Washing: Wash the plate three times with 0.05% (v / v) PBST. (9) Secondary antibody incubation: Add diluted anti-M13-HRP antibody (1:6000, diluted with blocking solution); add 100 μL to each well and incubate at 37°C for 1 hour. (10) Washing: Wash the plate with 0.05% (v / v) PBST for a total of three times. (11) Color development: Add 100 μL of TMB color development solution to each well and react for 20 minutes at room temperature in the dark. Then add 100 μL of 2M HCl stop solution to each well to terminate the reaction. (12) Reading: Detect the absorbance at 450 nm on an ELISA reader. Table 3 and Table 4 are the results of monoclonal phage ELISA in the experimental group and the control group respectively. The positive clones (underlined clones) in the table were sent for sequencing. Finally, 4 different sequences were obtained, and these positive clones were verified for the second time. Table 3. Results of monoclonal phage ELISA in experimental groups (Ag:IL1R2 protein, OD 450 ) Table 4. Results of monoclonal phage ELISA in the control group (NC: PBS, OD 450 ) 8. ELISA detection of positive clones (1) Take 50 μL of the positive clone detected in "7. Monoclonal phage ELISA detection" above and add 500 μL of 2×YT-AG medium for cultivation until OD 600 =0.4-0.6. (2) The culture medium was infected with M13KO7 (MOI = 20:1), incubated at 37°C for 30 min, and then shaken at 37°C for 30 min; centrifuged, then the supernatant was discarded, and an equal volume of 2×YT-AK medium (Amp 100 μg / mL, Kan 100 μg / mL) was added, and cultured at 37°C on a shaker overnight. (3) The culture medium obtained in step (2) is centrifuged and the supernatant can be used for ELISA detection. (4) Coating: The test plate was coated with antigen (4 μg / ml IL1R2 protein in the experimental group and PBS in the control group) at 4°C overnight. (5) Washing: The antigen-coated plate was washed twice with 0.05% (v / v) PBST and then washed once with PBS. (6) Blocking: The plate was blocked with 300 μL of 5% skim milk at 30°C for 2 h. (7) Incubation: Add 100 μL of the amplified phage after serial dilution and incubate at 37°C for 2 h. (8) Washing: Wash three times with 0.05% (v / v) PBST. (9) Secondary antibody incubation: Add diluted anti-M13-HRP antibody (1:6000, diluted with blocking solution); add 100 μL to each well and incubate at 37°C for 1 hour. (10) Washing: Wash the plate with 0.05% (v / v) PBST for a total of three times. (11) Color development: Add 100 μL of TMB color development solution to each well and react at room temperature in the dark for 20 min; then add 100 μL of 2M HCl stop solution to each well to terminate the reaction. The ELISA results of the four positive clones are shown in Table 5, and the obtained amino acid sequences of the heavy and light chains of the antibody variable regions are shown in Table 6 (the amino acid sequences of the CDRs were determined according to the IMGT definition rules). Table 5. ELISA results of positive clones Note: In Table 5, Ag1 is the experimental group and NC is the control group. Table 6. Amino acid sequences of variable regions of positive clones Table 7. CDR amino acid sequences of positive clones Embodiment 2 Recombinant expression of antibodies Through phage display technology, four clones, 3999-R3P1-B1, 3999-R3P1-H1, 3999-R3P1-E4, and 3999-R3P1-E11, were screened and their antibodies were expressed and purified. Subclone the screened sequences into the PATX1 vector to obtain full-length antibody light and heavy chains: The coding sequences of the heavy chain and light chain of 3999-R3P1-B1 are shown in SEQ ID NO:29 and SEQ ID NO:33, respectively; The coding sequences of the heavy chain and light chain of 3999-R3P1-H1 are shown in SEQ ID NO:30 and SEQ ID NO:34, respectively; The coding sequences of the heavy chain and light chain of 3999-R3P1-E4 are shown in SEQ ID NO:31 and SEQ ID NO:35, respectively. Show; The coding sequences of the heavy chain and light chain of 3999-R3P1-E11 are shown in SEQ ID NO:32 and SEQ ID NO:36, respectively. The prepared endotoxin-free DNA was then transfected into XtenCHO cells (the specific transfection scheme is shown in Table 8). After 14 days of transfection, the cell culture medium was collected and protein was purified. The purified antibody was subjected to qualitative and quantitative analysis by SDS-PAGE, and the results are shown in Figure 1. Table 8. Transfection methods of antibody plasmids Embodiment 3 ELISA detection of antibodies (1) Antigen coating Add 100 μl of 5 μg / mL antigen (the antigen is human hIL1R2 protein) to each well of the 96-well plate and incubate at 37°C for 2 h. After coating, the cells were washed twice with 0.05% (v / v) PBST and then once with PBS. (2) Closed Each well of the coated plate was blocked with 300 μL of 3% (v / v) BSA-PBS blocking solution at 37° C. for 1.5 h. (3) Cleaning The plates were patted dry and washed three times with 0.05% (v / v) PBST. (4) Primary antibody incubation The screened antibodies were diluted with PBST in a concentration gradient, 100 μL per well, and incubated at 37°C for 1 h. (5) Cleaning The plates were patted dry and washed three times with PBST. (6) Secondary antibody incubation Dilute goat anti-human (H+L) antibody (company: Cwbio, catalog number: CW0169S) at 1:10000, add 100 μl of the diluted antibody to each well of the plate in step (5), and incubate at 37°C for 0.5 h; then pat the plate dry and wash three times with PBST. (7) TMB color development Add TMB substrate (Company: Thermo Scientific, Catalog No.: TK2666052), 100 μL per well, react at 37°C in the dark for 10 min; then add 50 μL 2M HCl stop solution to each well to terminate; finally read the value at 450 nm on the microplate reader. The absorbance value. The results are shown in Figure 2: the screened antibodies can bind well to human IL1R2 protein. Embodiment 4 Evaluation of Anti-tumor Effects of Antibodies In order to evaluate whether the antibodies we screened have a certain anti-tumor effect, we subcutaneously transplanted MC38 tumor cells (derived from ATCC, a mouse colorectal cancer cell line) into C57BL / 6N mice. Five days after tumor transplantation (when the tumor was about 5×5mm 2 ) mice were intraperitoneally injected with the selected antibodies (3 mg / kg), with PBS as the control group, once every other day, for a total of three injections. Tumor measurement began on the 5th day. When the tumor size exceeded 300 mm 2 The measurement was stopped at 37 days, and the total measurement was up to day 37. It was found that three of the screened antibodies (3999-R3P1-B1, 3999-R3P1-E4, 3999-R3P1-E11) had certain anti-tumor effects (as shown in Figure 3). We then repeated the above experiment using the three antibodies 3999-R3P1-B1, 3999-R3P1-E4, and 3999-R3P1-E11. Each mouse was injected intraperitoneally six times, once every other day. Tumor measurements were performed starting on the fifth day, once every other day or every two days. When the tumor size exceeded 300 mm 2 The measurement was stopped at 3999-R3P1-B1 and 3999-R3P1-E4, and the two antibodies were found to have obvious anti-tumor effects (as shown in Figure 4), and could significantly improve the survival rate of mice (as shown in Figure 5). >3999-R3P1-B1-H (SEQ ID NO: 29, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-H1-H (SEQ ID NO: 30, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-E4-H (SEQ ID NO: 31, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-E11-H (SEQ ID NO: 32, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-B1-L (SEQ ID NO: 33, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-H1-L (SEQ ID NO: 34, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-E4-L (SEQ ID NO: 35, the underlined part is the variable region, and the rest is the constant region) >3999-R3P1-E11-L (SEQ ID NO: 36, the underlined part is the variable region, and the rest is the constant region) Heavy chain constant region (SEQ ID NO: 37) Light chain constant region (SEQ ID NO: 38) Human IL1R2 protein amino acid sequence (SEQ ID NO: 39): Nucleotide sequence of human IL1R2 (SEQ ID NO:40) References: [1]. Sakaguchi, S., N. Sakaguchi, M. Asano, et al., Immunologic self - tolerance maintained by activated T cells expressing IL - 2 receptor alpha - chains(CD25). Breakdown of a single mechanism of self - tolerance causes various autoimmune diseases. Journal of Immunology(Baltimore, Md.: 1950), 1995. 155(3): p. 1151 - 1164. [2]. Saleh, R. and E. Elkord, Acquired resistance to cancer immunotherapy: Role of tumor - mediated immunosuppression. Seminars In Cancer Biology, 2020. 65: p. 13 - 27. [3]. Collison, L. W., C. J. Workman, T. T. Kuo, et al., The inhibitory cytokine IL - 35 contributes to regulatory T - cell function. Nature, 2007. 450(7169): p. 566 - 569. [4]. Beissert, S., A. Schwarz, and T. Schwarz, Regulatory T cells. The Journal of Investigative Dermatology, 2006. 126(1): p. 15 - 24. [5]. Halvorsen, E. C., S. M. Mahmoud, and K. L. Bennewith, Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer Metastasis Reviews, 2014. 33(4): p. 1025 - 1041. [6].Liu,Y.and P.Zheng,Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.Trends In Pharmacological Sciences,2020.41(1). [7].Rowshanravan,B.,N.Halliday,and D.M.Sansom,CTLA-4:a moving target in immunotherapy.Blood,2018.131(1):p.58-67. [8].Korman,A.J.,S.C.Garrett-Thomson,and N.Lonberg,The foundations of immune checkpoint blockade and the ipilimumab approval decennial.Nature Reviews.Drug Discovery,2022.21(7):p.509-528. [9].Friedman,C.F.,T.A.Proverbs-Singh,and M.A.Postow,Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors:A Review.JAMA Oncology,2016.2(10):p.1346-1353.

[0010] .Garlanda,C.,C.A.Dinarello,and A.Mantovani,The interleukin-1 family:back to the future.Immunity,2013.39(6):p.1003-1018.

[0011] .Boraschi,D.,P.Italiani,S.Weil,et al.,The family of the interleukin-1 receptors.Immunological Reviews,2018.281(1):p.197-232.

[0012] .Chen,L.,H.Huang,X.Zheng,et al.,IL1R2 increases regulatory T cell population in the tumor microenvironment by enhancing MHC-II expression on cancer-associated fibroblasts.Journal for immunotherapy of cancer,2022.10(9):p.e004585.

[0013] .De Simone,M.,A.Arrigoni,G.Rossetti,et al.,Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells.Immunity,2016.45(5):p.1135-1147.

[0014] .Jaroszewicz,W.,J.Morcinek- K.Pierzynowska,et al.,Phage display and other peptide display technologies.FEMS Microbiology Reviews,2022.46(2).

[0015] .Saw,P.E.and E.-W.Song,Phage display screening of therapeutic peptide for cancer targeting and therapy.Protein&Cell,2019.10(11):p.787-807.

[0016] .Ribas,A.and J.D.Wolchok,Cancer immunotherapy using checkpoint blockade.Science(New York,N.Y.),2018.359(6382):p.1350-1355.

[0017] . Postow, MA, R. Sidlow, and MD Hellmann, Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. The New England Journal of Medicine, 2018.378(2):p.158-168. It should be noted that, although the technical solution of the present invention is introduced with specific examples, those skilled in the art will appreciate that the present invention should not be limited thereto. The embodiments of the present invention have been described above, and the above description is exemplary, not exhaustive, and is not limited to the disclosed embodiments. Many modifications and variations will be apparent to those of ordinary skill in the art without departing from the scope and spirit of the described embodiments. The selection of terms used herein is intended to best explain the principles of the embodiments, practical applications, or technical improvements in the market, or to enable other persons of ordinary skill in the art to understand the embodiments disclosed herein.

Claims

1. An anti-IL1R2 antibody or an antigen-binding fragment thereof, comprising a light chain variable region and a heavy chain variable region, wherein: The light chain variable region comprises LCDR1, LCDR2 and LCDR3 selected from any one of the following (a1) to (a4): (a1) LCDR1 as shown in SEQ ID NO:9, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO:10; (a2) LCDR1 as shown in SEQ ID NO: 11, LCDR2 as shown in sequence RNN, and LCDR3 as shown in SEQ ID NO: 12; (a3) LCDR1 as shown in SEQ ID NO: 13, LCDR2 as shown in sequence KVS, and LCDR3 as shown in SEQ ID NO: 14; or (a4) LCDR1 as shown in SEQ ID NO: 15, LCDR2 as shown in sequence GNS, and LCDR3 as shown in SEQ ID NO: 16; The heavy chain variable region comprises a HCDR1, a HCDR2 and a HCDR3 selected from any one of the following (b1) to (b4): (b1) HCDR1 as shown in SEQ ID NO: 17, HCDR2 as shown in SEQ ID NO: 18, and HCDR3 as shown in SEQ ID NO: 19; (b2) HCDR1 as shown in SEQ ID NO:20, HCDR2 as shown in SEQ ID NO:21, and HCDR3 as shown in SEQ ID NO:22; (b3) HCDR1 as shown in SEQ ID NO:23, HCDR2 as shown in SEQ ID NO:24, and HCDR3 as shown in SEQ ID NO:25; or (b4) HCDR1 as shown in SEQ ID NO:26, HCDR2 as shown in SEQ ID NO:27 and HCDR3 as shown in SEQ ID NO:

28.

2. The anti-IL1R2 antibody or antigen-binding fragment thereof according to claim 1, comprising a heavy chain variable region as shown in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7; and / or, It comprises a light chain variable region as shown in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:8, or a variant thereof having at least 70%, 75%, 80%, 85%, 90%, 95% or 99% or higher sequence identity with any one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6 or SEQ ID NO:

8.

3. The anti-IL1R2 antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein: The anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a heavy chain constant region derived from human IgG1, IgG2, IgG3 or IgG4 or a variant thereof; and / or, The anti-IL1R2 antibody or antigen-binding fragment thereof further comprises a light chain constant derived from a human kappa chain, a lambda chain or a variant thereof. district.

4. The anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the anti-IL1R2 antibody or antigen-binding fragment thereof comprises a human antibody; and / or, The anti-IL1R2 antibody or antigen-binding fragment thereof is selected from at least one of a full-length antibody, a Fab fragment, a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a single-chain antibody, and a multispecific antibody.

5. An isolated polynucleotide, wherein The polynucleotide encodes the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4.

6. An expression cassette, wherein The expression cassette comprises the polynucleotide of claim 5.

7. A recombinant vector, wherein: The recombinant vector comprises the polynucleotide according to claim 5 or the expression cassette according to claim 6.

8. A host cell, wherein The host cell comprises the polynucleotide of claim 5 , the expression cassette of claim 6 , or the recombinant vector of claim 7 .

9. The host cell according to claim 8, wherein The host cell is a microorganism or a mammalian cell; Optionally, the microorganism is selected from bacteria and / or yeast; Optionally, the mammalian cells are selected from HEK293T cells, HEK293F cells, HEK293 cells and / or CHO cells.

10. A bacteriophage, wherein: The phage surface displays the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4.

11. A method for preparing the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, comprising culturing the host cell according to claim 8 or 9 under conditions that allow the production of the anti-IL1R2 antibody or antigen-binding fragment thereof, and recovering and isolating the anti-IL1R2 antibody or antigen-binding fragment thereof.

12. A pharmaceutical composition comprising: the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, the polynucleotide according to claim 5, the expression cassette according to claim 6, the recombinant vector according to claim 7, or the host cell according to claim 8 or 9; and, Optionally, pharmaceutically acceptable carriers and / or excipients.

13. Use of the anti-IL1R2 antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, the polynucleotide according to claim 5, the expression cassette according to claim 6, the recombinant vector according to claim 7, the host cell according to claim 8 or 9, or the pharmaceutical composition according to claim 12 in the preparation of a medicament for treating an IL1R2-mediated disease or condition.

Citation Information

Patent Citations

  • Binding members against IL-1R1

    CN102307901A

  • Type ii interleukin-1 receptors

    WO1991018982A1

  • AU2012202672A1